+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage

Journal of Drugs in Dermatology 6(9): 910-914

Nodular basal cell carcinoma (nBCC) is the most common cutaneous malignancy and studies assessing the use of topical imiquimod 5% cream as a monotherapy in the treatment of nBCC have resulted in less than optimal clearance rates. This pilot study was designed to evaluate the efficacy of imiquimod 5% cream on nodular basal cell carcinoma lesions after initial treatment with curettage. After obtaining informed consent, 17 nBCCs on 15 patients were included in this institutional review board-approved, open-label study with initial treatment using curettage without electrodesiccation followed by once-daily application of imiquimod 5% cream 5 times per week for 6 weeks. The area was excised and examined histologically 6 weeks after cessation of imiquimod cream. All 17 lesions (100%) showed no histologic evidence of residual tumor on the post-treatment excision. Local site reactions necessitating a rest period from medication application were experienced by most patients (67%), but the majority of patients stated that they would choose this treatment modality over excision if they developed a subsequent tumor. Imiquimod 5% cream appears to be an effective treatment method for nodular basal cell carcinoma if combined with curettage prior to application.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 055009000

Download citation: RISBibTeXText

PMID: 17941362

Related references

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australasian Journal of Dermatology 47(1): 46-48, 2006

Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatologic Surgery 32(1): 63-69, 2006

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology 138(9): 1165-1171, 2002

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. Journal of Clinical and Aesthetic Dermatology 4(5): 39-43, 2011

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs. 2012

A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. Journal of Drugs in Dermatology 7(1 Suppl 1): S7, 2008

Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatology Nursing 21(2): 86-87, 2009

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. Bmc Ophthalmology 15: 35, 2015

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian Journal of Ophthalmology 65(1): 48-51, 2017

Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatology Online Journal 14(2): 25, 2008

Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFNalpha-2b and topical imiquimod 5% cream. International Journal of Dermatology 48(2): 214-215, 2009

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology 147(6): 1227-1236, 2002

Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefe's Archive for Clinical and Experimental Ophthalmology 249(1): 121-125, 2011

Successful Treatment of Giant Basal Cell Carcinoma with Topical Imiquimod 5% Cream with Long Term Follow-up. Indian Journal of Dermatology 59(6): 575-578, 2014

Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas. Dermatologic Surgery 30(3): 429-430, 2004